we have significant infrastructure development underway from a capital allocation standpoint, uh in terms of systems. So we'll continue to deploy cash for those purposes.

Jul 29, 2026 / receipt

we ended the first quarter with a total commercial organization of 146 sales representatives across all markets, reflecting continued disciplined expansion

Jul 29, 2026 / receipt

This guidance reflects continued confidence in commercial execution across all three core markets and the ongoing sales force productivity improvements.

Jul 29, 2026 / receipt

Looking ahead, we will continue to prioritize initiatives that strengthen our financial foundation, including targeted investments in innovation and commercial infrastructure. By maintaining a disciplined approach to expense management In leveraging economies of scale, we are confident in our ability to further enhance operating margins and deliver consistent profitability.

Feb 24, 2026 / receipt, needs a key / Lindsay Hartley, CFO | earnings call 2026-02-24 | transcript bb94ec8b-b3c0-46eb-9908-ea2c4ab0ce2d | chars 19200-19576 | segment 19

Our total operating expenses for the quarter decreased by 2.2% to $35.8 million, down from $36.6 million in Q2 of 2023. Then a decrease in total expenses was primarily the result of a reduction in R&D expenses, royalty fees, and travel costs.

Aug 8, 2024 / receipt, needs a key / Nir Naur, CFO | earnings call 2024-08-08 | transcript 195ba3a6-3e1e-4535-8fe3-9c7d449e4625 | chars 15229-15471 | segment 15

Subsequently, all interest charges are recorded as interest expense and other income and loss on our P&L. We are pleased with the operating leverage demonstrated through 2023, and we expect to continue trending towards cash flow breakeven driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.

Nov 7, 2023 / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-11-07 | transcript 39b8c9de-454b-4856-9a2a-966799155275 | chars 15383-15733 | segment 15

The increase was primarily due to compensation, marketing programs, and travel.

Nov 7, 2023 / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-11-07 | transcript 39b8c9de-454b-4856-9a2a-966799155275 | chars 13466-13545 | segment 13

We expect to continue trending towards cash flow breakeven, driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.

Aug 7, 2023 / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-08-07 | transcript 336014fe-05a9-4e92-9cd7-3bb67248000e | chars 21435-21606 | segment 21

We anticipate spending $1.7 to $2.7 million to complete the APC facility, primarily in the second quarter. We also expect our operating cash flow to continue trending towards breakeven, driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.

May 9, 2023 / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-05-09 | transcript e37eca42-27f7-4eeb-8bda-3167c1bbb1bf | chars 15962-16259 | segment 15

We expect our operating cash to continue trending towards cash flow break-even, driven by revenue leverage on our fixed-cost infrastructure, along with our continued focus on thoughtful operating expense management.

Nov 8, 2022 / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-11-08 | transcript 7c0d0e6f-cc72-47bc-8871-df1faf6c4b40 | chars 16365-16580 | segment 16

Total operating expense in the second quarter increased 7% to $36.1 million, compared to $33.6 million in the prior year. The increase in total operating expenses was primarily the result of an increased product development and clinical programs, as well as total compensation, including non-cast stock comp and travel costs.

Aug 3, 2022 / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-08-03 | transcript 7c2c9db7-14cd-44c2-90dd-76e3b425e176 | chars 12720-13045 | segment 12

Sales and marketing expense in the second quarter increased 2% to $19.7 million compared to $19.3 million in the prior year. The increase was primarily due to increased sales travel.

Aug 3, 2022 / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-08-03 | transcript 7c2c9db7-14cd-44c2-90dd-76e3b425e176 | chars 13046-13228 | segment 12

The increase in total operating expenses was primarily due to increased sales and project-related headcount, and the return of in-person sales team and physician meetings and education events, travel, and increased professional services spending.

May 4, 2022 / receipt, needs a key / Pete, CFO | earnings call 2022-05-04 | transcript 90f94f41-83df-4256-bb37-af6c2311ead2 | chars 19547-19793 | segment 19

The increase was primarily due to marketing development programs, compensation-related and travel-related expenses, from increased sales activity with greater hospital access.

May 4, 2022 / receipt, needs a key / Pete, CFO | earnings call 2022-05-04 | transcript 90f94f41-83df-4256-bb37-af6c2311ead2 | chars 19918-20093 | segment 20

The decrease is primarily due to a reduction in employee compensation where decreases in incentive and stock compensation bonus and commissions were partially offset by increases in salaries. The net decrease in operating expense was partially offset by increases in professional and consulting fees, marketing programs and travel, and research and development projects.

Feb 22, 2022 / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-02-22 | transcript 7e2d8acb-0da4-44ce-99f7-daf04966cf53 | chars 12522-12892 | segment 12

General and Administrative Expenses 13.4 9.7

ir_statement / Sep 15, 2026 / receipt

Research and Development Expenses 8.6 6.9

ir_statement / Sep 15, 2026 / receipt

Sales and Marketing Expenses $30.8 $23.8

ir_statement / Sep 15, 2026 / receipt

Revenue growth of at least 24% or $279 million

ir_statement / Sep 15, 2026 / receipt

Continuous business model and customer creation process optimization by market

ir_statement / Sep 15, 2026 / receipt

Infrastructure and Sales Force expansion

ir_statement / Sep 15, 2026 / receipt

2026 Breast / Ext. Grow to ~30 breast reps; ~130 extremity reps

ir_statement / Sep 15, 2026 / receipt

Accelerating growth driven by market development, sales force expansion, and coverage; growth >50% YoY

ir_statement / Sep 15, 2026 / receipt

Q2 Adjusted EBITDA* $8.4M, -4.2 pp as a percent of revenue YoY

ir_statement / Sep 15, 2026 / receipt

added 130+ active surgeons YTD

ir_statement / Sep 15, 2026 / receipt

Pursue near-universal US coverage (est. 2H 2028)

ir_statement / Sep 15, 2026 / receipt

train 300 surgeons and 75 surgeon pairs

ir_statement / Sep 15, 2026 / receipt